LOADING
Comparing Johnson & Johnson (JNJ) and Pfizer Inc (PFE), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | PFE |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $618.6B | $137.8B |
| P/E Ratio | 29.8 | 18.4 |
| Forward P/E | 22.2 | 8.2 |
| PEG Ratio | 4.94 | 2.83 |
| EPS | $8.63 | $1.31 |
| Revenue Growth (YoY) | 9.9% | 5.4% |
| Profit Margin | 21.8% | 11.8% |
| Return on Equity | 26.4% | 8.3% |
| Dividend Yield | 2.01% | 7.09% |
| Beta | 0.23 | 0.31 |
| 52-Week High | $269.43 | $28.28 |
| 52-Week Low | $155.89 | $21.97 |
| Volume | -- | -- |
Johnson & Johnson is the larger company by market capitalization. Pfizer Inc trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Pfizer Inc offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.